Brian Schwartz, M.D.

Dr. Schwartz has over 25 years of experience as a drug development expert in pharmaceutical and biotechnology industries and has served as Infinity’s consulting Chief Physician since early 2020.  He was previously at ArQule for 10 years where he served as CMO prior to the acquisition by Merck & Co. of ArQule in late 2019.  In senior leadership roles at ArQule, Ziopharm Oncology, Inc., Bayer AG, and LeoLabs, Inc., Dr. Schwartz has accumulated a number of successful new drug applications (NDAs), numerous investigational new drug (IND) applications, preclinical and clinical drug development programs.  During his time in biotech, Dr. Schwartz acquired knowledge of investors relations, partnering and capital raising.  Currently, in addition to the Infinity Board of Directors, Dr. Schwartz is a board member of Mereo Biopharma, Enlivex and Cyclacel pharmaceuticals and an advisor in different capacities to numerous biotech companies.  Dr. Schwartz qualified as a medical doctor in South Africa followed by additional fellowship training in Canada.